Expertise in
10
conditions

Karl-ludwig L. Laugwitz

Ismaninger Str. 22, 
Munich, BY, DE 
Expertise in
10
conditions
Ismaninger Str. 22, 
Munich, BY, DE 
OverviewLocationsClinical Research

Overview

Karl-ludwig Laugwitz practices in Munich, Germany. Laugwitz is highly rated in 10 conditions, according to our data. Their top areas of expertise are Coronary Heart Disease, Heart Attack, Acute Coronary Syndrome, Stent Placement, and Percutaneous Coronary Intervention (PCI).

Their clinical research consists of co-authoring 372 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Ismaninger Str. 22, Munich, BY 81675, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

PRediction of Acute Coronary Syndrome in Acute Ischemic StrokE
PRediction of Acute Coronary Syndrome in Acute Ischemic StrokE
Enrollment Status: Completed
Publish Date: March 26, 2025
Intervention Type: Diagnostic test
Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome - Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5
Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome - Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5
Enrollment Status: Completed
Publish Date: February 06, 2023
Intervention Type: Drug
Study Drugs: Ticagrelor, Prasugrel
Study Phase: Phase 4
Revacept, a Novel Inhibitor of Platelet Adhesion in Patients With Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Interventions: a Phase II, Multicentre, Randomised, Double-blind and Placebo-controlled Study
Revacept, a Novel Inhibitor of Platelet Adhesion in Patients With Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Interventions: a Phase II, Multicentre, Randomised, Double-blind and Placebo-controlled Study
Enrollment Status: Completed
Publish Date: April 20, 2020
Intervention Type: Drug
Study Phase: Phase 2
Intracoronary Stenting and Angiographic Results: ORSIRO Stents Versus Xience PRIME Stents Assessed by Optical Coherence Tomography
Intracoronary Stenting and Angiographic Results: ORSIRO Stents Versus Xience PRIME Stents Assessed by Optical Coherence Tomography
Enrollment Status: Completed
Publish Date: August 04, 2017
Intervention Type: Device, Drug
Study Phase: Phase 4
View 3 Less Clinical Trials

372 Total Publications

Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets.
Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets.
Journal: European heart journal
Published: August 20, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Laugwitz's expertise for a condition
ConditionClose
    View All 42 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile